Advertisement

Topics

Themis Bioscience Company Profile

20:20 EDT 21st October 2018 | BioPortfolio

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine and immune activation technology has created a powerful platform and a growing pipeline addressing a broad range of infectious diseases. Together with industrial and academic leaders we work to prevent illness across the globe. For more information, visit http://www.themisbio.com.


News Articles [304 Associated News Articles listed on BioPortfolio]

Themis Bioscience Announces Exclusive Licensing Agreement with Max-Planck-Innovation to Develop ...

-- Themis to expand measles vector immunomodulation portfolio into oncology indications-- Read more...

Themis gets oncology-related IP from Max Planck

Max Planck Innovation GMBH licensed Themis Bioscience GMBH exclusive worldwide rights to develop, manufacture, and commercialize cancer therapies based on an oncolytic measles virus platform.

Max Planck Partners with Themis Bioscience to Develop Oncolytic Virotherapies

Themis Bioscience said it will expand its measles vector immunomodulation portfolio into immuno-oncology through an exclusive global license agreement with the technology transfer agency of the Max Pl...

CHIKUNGUNYA VACCINE DEVELOPMENT TOWARDS PHASE III TRIALS BOOSTED BY INNOVATE UK

Vienna, 5th September 2017 – The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom’s innovation agenc...

EMA grants PRIME designation to Themis' chikungunya vaccine candidate

Themis announced today that the European Medicines Agency has granted PRIority MEdicines designation to its most advanced program in development, a vaccine to prevent chikungunya fever.

Themis Receives EMA PRIME Designation for Chikungunya Vaccine

Themis announced today that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its most advanced program in development, a vaccine to...

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwid...

Themis bags vaccine license

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

O24 [Revive Bioscience, Inc.]

Abraxane [Abraxis BioScience, LLC]

These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing information for ABRAXANE ABRAXANE® for Injectable Suspension (paclitaxel protei...

Idkit hp one [Exalenz Bioscience Ltd.]

Package Insert IDkit:Hp™ for the Exalenz BreathID® System BREATH TEST FOR DETECTION of H. pylori

PubMed Articles [66 Associated PubMed Articles listed on BioPortfolio]

Improving Undergraduate Life Science Education for the Biosciences Workforce: Overcoming the Disconnect between Educators and Industry.

The BioHealth Capital Region (Maryland, Virginia, and Washington, DC; BHCR) is flush with colleges and universities training students in science, technology, engineering, and mathematics disciplines a...

Youtube for millennial nursing students; using internet technology to support student engagement with bioscience.

Undergraduate nursing programs typically include students with limited 'on-campus' time who need learning resources that are flexible, technologically appropriate, remotely-accessible (mobile smart de...

Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal γδ T cell's Th17 response.

This study investigated the role of HSP70 in modulating intestinal γδ T cells' Th17 response in -induced PI-IBS mice model.

Resveratrol enhances matrix biosynthesis of nucleus pulposus cells through activating autophagy via the PI3K/Akt pathway under oxidative damage.

The decrease in nucleus pulposus (NP) matrix production is a classic  feature during disc degeneration. Resveratrol (RSV) is reported to play protective effects under many pathological factors.

A temporal examination of calcium signaling in cancer- from tumorigenesis, to immune evasion, and metastasis.

Although the study of calcium (Ca) is classically associated with excitable cells such as myocytes or neurons, the ubiquity of this essential element in all cellular processes has led to interest in o...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Metabolic syndrome increases the risk for development of heart disease. Another condition associated with metabolic syndrome is fatty liver disease which is also referred to as nonalcoholi...

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patie...

Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol

This pilot study will try to minimize the pain during exposure to a new red light source (RhodoLED®, Biofrontera Bioscience GmbH, Leverkusen, Germany) used for PDT without compromising it...

Skin Safety Profile of Different Exposure to the Light Emitting Diode (LED) in Healthy Subjects

Photomodulation is a process which manipulates or regulates cell activity using light sources without thermal effect. Different studies have investigated the use of non-thermal low dose li...

Companies [313 Associated Companies listed on BioPortfolio]

Themis Bioscience

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating...

Themis

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating...

The Idaho Bioscience Association

The Idaho Bioscience Association is a non-profit organization that brings together corporate, academic and political leaders to educate the public and to promote bioscience activities in the state. B...

Sprint Bioscience

Sprint Bioscience AB (publ) is part of the new Swedish pharmaceutical industry. The company has the goal to develop drug candidates for the global pharmaceutical market within the...

Bioscience Bridge, LLC

Bioscience Bridge, LLC is a global technology transfer agency. We accelerate the connections of university-based bioscience research with commercial development opportunities. We are unique because we...

More Information about "Themis Bioscience" on BioPortfolio

We have published hundreds of Themis Bioscience news stories on BioPortfolio along with dozens of Themis Bioscience Clinical Trials and PubMed Articles about Themis Bioscience for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Themis Bioscience Companies in our database. You can also find out about relevant Themis Bioscience Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Corporate Database Quicklinks



Searches Linking to this Company Record